Recent advances in cell biology, diagnosis and therapy of gastrointestinal stromal tumor (GIST)

Cancer Biology and Therapy

Volumn 3, Issue 3, 2004, Pages 251-258

  Logroño, Roberto ^a   Jones, Dennie V ^a   Faruqi, Sohaib ^b   Bhutani, Manoop S ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cell biology; Diagnosis; Gastrointestinal stromal tumor; Gastrointestinal tract; GIST; Imatinib mesylate; Therapy

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; MITOMYCIN C; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR CELL; BIOSYNTHESIS; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; ENZYME INHIBITORS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 4944225838     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.3.615     Document Type: Review

References (78)

1. Hunt GC, Rader AE, Faigel DO. A comparison of EUS features between CD-117 positive G1 stromal tumors and CD-117 negative GI spindle cell tumors. Gastrointest Endosc 2003; 57:469-74.
2. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with reference to CD117 (kit). Mod Pathol 2000; 13:1134-42.
3. Stelow EB, Stanley MW, Mallery S, Lai R, Linzie BM, Bardales RH. Endoscopic ultrasound-guided fine needle aspiration findings of gastrointestinal leiomyomas and gastrointestinal stromal tumors. Am J Clin Pathol 2003; 119:703-8.
4. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-8.
5. Miettinen M, Lasota J. KIT expression in angiosarcomas and in fetal endothelial cells. Lack of c-kit mutations in exons 11 and 17 in angiosarcoma. Mod Pathol 2000; 13:536-41.
6. Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C, et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92:657-62.
7. Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120:210-5.
8. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19:323-4.
9. Carney JA. The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma: A five-year review. Medicine 1983; 62:159-69.
10. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): Natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999; 74:543-52.
11. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol 1999; 30:1213-20.
12. Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003; 16:366-75.
13. Appelman HD. Mesenchymal tumors of the gastrointestinal tract. In: Ming SC, Goldman H, eds. Pathology of the gastrointestinal tract, 2nd ed. Baltimore: Williams & Wilkins, 1998:362-4.
14. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103:41-7.
15. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50-9.
16. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic study. Hum Pathol 1998; 29:791-800.
17. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000; 88:66-74.
18. Appleman H, Helwig EB. Cellular leiomyomas of the stomach in 49 patients. Arch Pathol Lab Med 1977; 101:373-7.
19. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7:507-19.
20. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-69.
21. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23:377-89.
22. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11:728-34.
23. Vliagoftis H, Worobec AS, Metcalfe DD. The proto-oncogene c-kit and c-kit ligand in human disease. J Allergy Clin Immunol 1997; 100:435-40.
24. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CDM, et al. ST1571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: Biological and clinical implications. Oncogene 2001; 20:5054-8.
25. Lozano MD, Rodriguez J, Martin Algarra S, Panizo A, Sola JJ, Pardo J. Fine needle aspiration cytology and immunocytochemistry in the diagnosis of 24 gastrointestinal stromal tumors: A quick, reliable diagnostic method. Diagn Cytopathol 2003; 28:131-5.
26. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fufuda T, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: Immunohistochemical study of formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424:135-41.
27. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997; 10:939-44.
28. EkforsT, Kujari H, Isomaki M. Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) in the duodenum: The first visceral case. Histopathology 1993; 22:255-9.
29. Miettinen M, Virolainen M, Sarlomo-Rikala M. Gastrointestinal stromal tumors : Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19:207-16.
30. Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors. A study of 27 cases. Arch Pathol Lab Med 2000; 124:1471-5.
31. Vanderwinden J-M, Rumessen JJ, De Laet M-H, Vanderhaeghen JJ, Schiffmann SN. CD34+ cells in human intestine are fibroblasts adjacent to, but distinct from, interstitial cells. Lab Invest 1999; 79:59-65.
32. Kitamura Y, Hiroda S, Nishida T. Molecular pathology of c-KIT proto-oncogene and development of gastrointestinal stromal tumors. Ann Chir Gynaecol 1998; 87:282-6.
33. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118-21.
34. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567-72.
35. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
36. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T. Nomura T, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297-300.
37. Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O'Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry. Am J Surg Pathol 1993; 17:588-94.
38. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am J Surg Pathol 1999; 23:82-7.
39. Chak A, Canto MI, Rosch T, Ditter HJ, Hawes RH, Tio TL, et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc 1997; 45:468-73.
40. Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T, et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002; 55:37-43.
41. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24:211-22.
42. Tworek JA, Appelman HD, Singleton TP, Greenson JK. Stromal tumors of the jejunum and ileum. Mod Pathol 1997; 10:200-9.
43. Brainard JA, Goldblum JR. Stromal tumors of the jejunum and ileum: A clinicopathologic study of 39 cases. Am J Surg Pathol 1997; 21:407-16.
44. Tworek JA, Goldblum JR, Weiss SW, Greenson JK, Appleman HD. Stromal tumors of the abdominal colon. Am J Surg Pathol 1999; 23:937-45.
45. Haque S, Dean PJ. Stromal neoplasms of the rectum and anal canal. Hum Pathol 1992; 23:762-7.
46. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25:1121-33.
47. Carrillo R, Candis A, Rodríguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28:160-5.
48. Bhutani MS, ed. Interventional Endoscopic Ultrasonography. Amsterdam: Harwood Academic Publishers, 1999.
49. Pallazo L, Landi B, Cuillerier E, Roseau G, Barbier JP. Endosonographic features of benign and malignant gastrointestinal stromal cell tumours. Gut 2000; 46:88-92.
50. Shen EF, Arnott IDR, Plevris J, Penman ID. Endoscopic ultrasonography in the diagnosis and management of suspected upper gastrointestinal submucosal tumours. Br J Surg 2002; 89:231-5.
51. Giovannini M, Seitz JF, Monges G, Perrier H, Rabbia I. Fine needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients. Endoscopy 1995; 27:171-7.
52. Wiersema MJ, Vilmann P, Giovannini M, Chang KJ, Wiersema LM. Endosonography-guided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment. Gastroenterology 1997; 112:1087-95.
53. Logroño R, Waxman I. Interactive role of the cytopathologist in EUS-guided fine needle aspiration: An efficient approach. Gastrointest Endosc 2001; 54:485-90.
54. Klapman JB, Logroño R, Dye CE, Waxman I. Clinical impact of on-site cytopathology interpretation on endoscopic ultrasound-guided fine needle aspiration (EUS-guided FNA). Am J Gastroenterol 2003; 98:1289-94.
55. Tao L-C, Davidson DD. Aspiration biopsy cytology of smooth muscle tumors. A cytologic approach to the differentiation between leiomyosarcoma and leiomyoma. Acta Cytol 1993; 37:300-8.
56. Das DK, Pant CS. Fine needle aspiration cytologic diagnosis of gastrointestinal tract lesions. A study of 78 cases. Acta Cytol 1994; 38:723-9.
57. Boggino HE, Fernandez MP, Logroño R. Cytomorphology of gastrointestinal stromal tumor: Diagnostic role of aspiration cytology, core biopsy, and immunochemistry. Diagn Cytopathol 2000; 23:156-60.
58. Dodd LG, Nelson RC, Mooney EE, Gottfried M. Fine-needle aspiration of gastrointestinal stromal tumors. Am J Clin Pathol 1998; 109:439-43.
59. Seidal T, Edvardsson H. Diagnosis of Gastrointestinal stromal tumor by fine-needle aspiration biopsy: A cytological and immunocytochemical study. Diagn Cytopathol 2000; 23:397-401.
60. King R, Quinonez GE, Gough JG. Fine needle aspiration biopsy diagnosis of gastrointestinal stromal tumor utilizing transmission electron microscopy. Acta Cytol 1996; 40:581-4.
61. Wieczorek TJ, Faquin WC, Rubin BP, Cibas ES. Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma. Cancer Cytopathol 2001; 93:276-87.
62. Dong Q, McKee G, Pitman M, Geisinger K, Tambouret R. Epithelioid variant of gastrointestinal stromal tumor: Diagnosis by fine needle aspiration. Diagn Cytopathol 2003; 29:55-60.
63. Li SQ, O'Leary TJ, Buchner S-B, Przygodzki RM, Sobin LH, Erozan YS, et al. Fine needle aspiration of gastrointestinal stromal tumors. Acta Cytol 2001; 45:9-17.
64. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7:705-12.
65. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215:68-77.
66. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33:466-77.
67. Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 1996; 119:171-7.
68. Sturgeon C, Chejfec G, Espat NJ. Gastrointestinal stromal tumors: A spectrum of disease. Surg Oncol 2003; 12:21-6.
69. Karakousis CP, Blumenson LE, Canavese G, Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg 1992; 103:560-4.
70. Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998; 2:151-5.
71. Edmonson J, Marks R, Buckner J, Mahoney M. Contrast of Response to D-MAP + Sargramostim Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas (Meeting abstract). Proc of Am Assoc Cancer Res 1999; 18:541.
72. Zalupski M, Metck B, Balcerzak S, Fletcker WS, Chapman R, Bonnet JD, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study. J Nat Cancer Instit 1991; 83:926-32.
73. Blair SC, Zalupski MM, Baker LH. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 1994; 17:480-4.
74. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7.
75. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80.
76. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donate di Paola E, Dimitrijevic S, et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358:1421-3.
77. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38:S60-5.
78. Heinrick MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-703.